

# FORM 11

## NOTICE OF PROPOSED STOCK OPTION GRANT OR AMENDMENT

Name of Listed Issuer: Pharmadrug Inc. (the "Issuer").

Trading Symbol: PHRX

Date: April 16, 2024

### 1. New Options Granted:

Date of Grant: April 12, 2024

Name of Optionee	Position (Director/ Officer/ Employee/ Consultant/ Management Company)	Insider Yes or No?	No. of Optioned Shares	Exercise Price	Expiry Date	No. of Options Granted in Past 12 Months
Kelly Abbott	Consultant	No	1,200,000	\$0.05	April 12, 2026	N/A

Total Number of optioned shares proposed for acceptance: 1,200,000.

## 2. Other Presently Outstanding Options:

Name of Optionee	No. of Optioned Shares <sup>(1)</sup>	Exercise Price	Original Date of Grant	Expiry Date
Jeffrey Stevens	71,429	\$0.77	31-May-20	31-May-25
Paul McClory	71,429	\$0.35	Aug 31, 2020	Aug 31, 2025
Nikolai Vassev	71,429	\$0.35	Aug 31, 2020	Aug 31, 2025
2653438 Ontario Inc.	142,857	\$0.42	Dec 8, 2020	Dec 8, 2025
Paul McClory	71,429	\$0.60	Feb 4, 2021	Feb 4, 2026
Nikolai Vassez	71,429	\$0.60	Feb 4, 2021	Feb 4, 2026
Rody Lazar	14,286	\$0.60	Feb 4, 2021	Feb 4, 2026
David Kideckel	107,143	\$0.42	August 30,2021	August 30, 2026
Robert Steen	3,000,000	\$0.055	Nov 7, 2023	Nov 7, 2028
David Kideckel	1,000,000	\$0.055	Nov 7, 2023	Nov 7, 2028
Paul McClory	750,000	\$0.055	Nov 7, 2023	Nov 7, 2028
Nikolai Vassev	500,000	\$0.055	Nov 7, 2023	Nov 7, 2028
Kyle Appleby	500,000	\$0.055	Nov 7, 2023	Nov 7, 2028
Ian Cochrane	500,000	\$0.055	Nov 7, 2023	Nov 7, 2028
David Moses	500,000	\$0.05	Dec 11, 2023	Dec 11, 2025
Zacariah Goldman	500,000	\$0.05	Dec 11, 2023	Dec 11, 2025
Stephen Mortfield	100,000	\$0.05	Dec 11, 2023	Dec 11, 2025

(1) Set out number of optioned shares for each grant with different terms (adjusted for consolidated October 24, 2023).

## 3. Additional Information

- (a) If shareholder approval was required for the grant of options (including prior approval of a stock option plan), state the date that the shareholder meeting approving the grant was or will be held. N/A; shareholder approval not required.
- (b) State the date of the news release announcing the grant of options.  
April 16, 2024
- (c) State the total issued and outstanding share capital at the date of grant or amendment. 104,556,647

- (d) State, as a percentage of the issued and outstanding shares of the Issuer indicated in (c) above, the aggregate number of shares that are subject to incentive stock options, including new options, amended options and other presently outstanding options.
- (e) If the new options are being granted pursuant to a stock option plan, state the number of remaining shares reserved for issuance under the plan. 1,027,093
- (f) If the Issuer has completed a public distribution of its securities within 90 days of the date of grant, state the per share price paid by the public investors.  
N/A
- (g) Describe the particulars of any proposed material changes in the affairs of the Issuer. N/A

#### 4. Certificate of Compliance

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 11 Notice of Proposed Stock Option Grant or Amendment is true.

Dated April 16, 2024 .

Kyle Appleby

Name of Director or Senior  
Officer

"Kyle Appleby"

Signature

Chief Financial Officer

Official Capacity